How much funding has Metacrine raised?

Metacrine has raised $123.0M in total funding, most recently a Series C round.

Who are Metacrine's investors?

Metacrine's investors include Alexandria Venture Investments, ARCH Venture Partners, Polaris Partners, venBIO Partners, Lilly Asia Ventures, Venrock.

Where is Metacrine headquartered?

Metacrine is headquartered in San Diego, California, United States.

What industry is Metacrine in?

Metacrine operates in Biotech, Therapeutics.

Metacrine

IPO

Nuclear receptor therapies for liver and metabolic disease

Public · San Diego, United States · Founded 2015 · $123.0M raised

Biotech

Therapeutics

Headquarters: San Diego, California
Employees: 11–50
Founded: 2015
Business Model: B2B
Website: metacrine.com

Total Funding: $123.0M
Last Round: $65.0M Series CJun 2018
Rounds: 3
Type: Public

About

Metacrine is a clinical-stage biopharmaceutical company focused on developing therapies for patients with liver, gastrointestinal, and metabolic diseases. The company targets nuclear receptors involved in disease pathways, with a pipeline aimed at conditions such as NASH and inflammatory bowel disease.

Summary

Metacrine is a Biotech company based in San Diego, United States, founded in 2015. It has raised $123.0M in total across 3 rounds, most recently a $65.0M Series C round in Jun 2018. Investors include Alexandria Venture Investments, ARCH Venture Partners and Polaris Partners.